An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer

Despite novel drugs, the prognosis for patients with metastatic gastric cancer remains poor. In rare instances, locoregional therapies are used in addition to standard chemotherapy in patients with oligometastatic involvement. This type of approach has not been supported by solid published evidence....

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2021-04, Vol.21 (4), p.267-267, Article 267
Main Authors: Giampieri, Riccardo, Cantini, Luca, Del Prete, Michela, Bittoni, Alessandro, Giglio, Enrica, Mandolesi, Alessandra, Maccaroni, Elena, Lanese, Andrea, Meletani, Tania, Baleani, Maria Giuditta, Bisonni, Renato, Scarpelli, Marina, Berardi, Rossana
Format: Article
Language:English
Subjects:
Abdomen
Analysis
Cancer
Cancer patients
Care and treatment
Chemotherapy
Clinical outcomes
Colorectal cancer
Development and progression
Gastric cancer
Gastrointestinal surgery
Health aspects
Liver
Lymphatic system
Medical prognosis
Metastasis
Oncology
Patients
Pertuzumab
Prognosis
Software
Stomach cancer
Survival analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite novel drugs, the prognosis for patients with metastatic gastric cancer remains poor. In rare instances, locoregional therapies are used in addition to standard chemotherapy in patients with oligometastatic involvement. This type of approach has not been supported by solid published evidence. The aim of the present retrospective study was to assess the prognostic impact of factors such as metastatic site, tumour histology and locoregional treatment in patients with metastatic gastric cancer. A total of 184 patients with metastatic gastric or gastroesophageal junction adenocarcinoma who received at least one line of palliative therapy with doublet or triplet chemotherapy were enrolled in the current analysis. Median overall survival (OS) was 8.32 months (95% CI, 7.02-9.41) and median progression-free survival (PFS) was 4.16 months (95% CI, 3.24-5.08). Lung metastases vs. other sites of metastatic involvement [hazard ratio (HR), 0.27; P=0.0133] and intestinal histology (HR, 0.48; P=0.08) were significantly associated with an improved OS. Improved PFS was also observed (HR, 0.49; P=0.10 and HR, 0.72; P=0.08 for lung metastases and intestinal histology, respectively). Second line chemotherapy and locoregional treatment of metastases (surgery or radiotherapy) were associated with improved OS (HR, 0.52; P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2021.12528